1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Two Elephants In The Q3 Room

Market Access And Opposing Forces Affect Post-Pandemic Sales

 
• By Andy Smith

New product launches come with great expectations, which are sometimes unrealistic. This can lead to disappointment. Lately, market access restrictions are exacerbating sales challenges.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Sales of GLP-1 agonists for diabetes and obesity, and products to treat and prevent COVID-19, should continue to influence the earnings seasons for pharmaceutical companies in 2024.

A recent analysis of pharmaceutical product launches by the IQVIA Institute noted that average monthly gross sales over the first year on the market for newly launched products reached an all-time high in 2022 and is predicted to come close to that for products launched in 2023. But if the launches of the GLP-1 agonists for the treatment of diabetes and obesity in 2023 and 2023 were excluded, sales of products launched since 2022 fell significantly below the average monthly sales of drugs launched between 2013 and 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.